| Companies sponsors |
Ipsen (cabozantinib) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Bowel Cancer UK |
| |
Neuroendocrine Cancer UK |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Society for Endocrinology |
| |
UKI NETS |
| Associated public health groups |
None |
| Comparator companies |
Accord Healthcare (5-fluorouracil, temozolomide) (confidentiality agreement not signed, not participating) |
| |
Amarox (capecitabine) (confidentiality agreement not signed, not participating) |
| |
Baxter (doxorubicin) (confidentiality agreement not signed, not participating) |
| |
Dr Reddy’s Laboratories (capecitabine, everolimus, sunitinib) (confidentiality agreement not signed, not participating) |
| |
Esteve Pharmaceuticals (streptozocin) (confidentiality agreement not signed, not participating) |
| |
Ethypharm UK (everolimus) (confidentiality agreement not signed, not participating) |
| |
Glenmark Pharmaceuticals (capecitabine) (confidentiality agreement not signed, not participating) |
| |
Hospira UK (carboplatin, cisplatin, 5-fluorouracil) (confidentiality agreement not signed, not participating) |
| |
medac GmBH (doxorubicin, 5-fluorouracil,) (confidentiality agreement not signed, not participating) |
| |
Merck Sharp & Dohme (temozolomide) (confidentiality agreement not signed, not participating) |
| |
MSN Laboratories (sunitinib) (confidentiality agreement not signed, not participating) |
| |
Mylan (sunitinib) (confidentiality agreement not signed, not participating) |
| |
Neon Healthcare (etoposide) (confidentiality agreement not signed, not participating) |
| |
Novartis (everolimus, lutetium (177Lu) oxodotreotide) (confidentiality agreement not signed, not participating) |
| |
Pfizer (doxorubicin, sunitinib) (confidentiality agreement not signed, not participating) |
| |
Piramal Critical Care (sunitinib) (confidentiality agreement not signed, not participating) |
| |
Sandoz (cisplatin, everolimus, sunitinib) (confidentiality agreement not signed, not participating) |
| |
Seacross (doxorubicin) (confidentiality agreement not signed, not participating) |
| |
Sun Pharma (temozolomide) (confidentiality agreement not signed, not participating) |
| |
Teva Pharma (sunitinib) (confidentiality agreement not signed, not participating) |
| |
Zentiva (sunitinib) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
NHS Wales Joint Commissioning Committee |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| Relevant research groups |
None |